Skip to Content

Call for Applications: Senior Sponsored Research Administrator, Harvard Law School

Deadline: Open until filled.

Job-Specific Responsibilities Reporting to the Associate Dean for Finance/CFO, the Senior Sponsored Programs Administrator engages with Harvard Law School’s research programs and faculty-sponsored research areas as a…

Compensating for research risk image

Compensating for research risk: permissible but not obligatory

Holly Lynch Fernandez (Former Executive Director) and Emily A. Largent (Former Student Fellow)
Journal of Medical Ethics

When payment is offered for controlled human infection model (CHIM) research, ethical concerns may be heightened due to unfamiliarity with this study design as well as perceptions—and misperceptions…

Private Funding of Drug Discovery: Ethical Issues, Practical Alternatives image

Private Funding of Drug Discovery: Ethical Issues, Practical Alternatives: A Health Policy and Bioethics Consortium

March 13, 2020

Description The traditional model for drug development begins with publicly-funded science based in academic or government laboratories before private investors and for-profit pharmaceutical manufacturers become involved with their substantial expertise…

Economic vulnerability and payment for research participation image

Economic vulnerability and payment for research participation

Luke Gelinas (Former Senior Researcher), Sarah White, Barbara Bierer
Journal of the Society for Clinical Trials

Abstract: There has been significant analysis of the ethical and regulatory issues involved with paying research participants, but less attention has been focused specifically on paying economically vulnerable individuals and…

First Opinion: Do large pharma companies provide drug development innovation? image

First Opinion: Do large pharma companies provide drug development innovation?: Our analysis says no

Emily H. Jung (former intern), Alfred Engelberg, and Aaron S. Kesselheim
STAT

From the article: Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug…

Apple’s Reach Reshapes Medical Research: The company’s tools enable researchers to track huge numbers of people. But doctors do not yet know if it will significantly improve health outcomes.

Natasha Singer
New York Times

[...] The new ingredients allowing the huge scale: Apple’s iPhones, apps and money. Harvard’s new study is just one of three new large research efforts that Apple…

Celebrating the pursuit of scientific innovation image

Celebrating the pursuit of scientific innovation: We should all be thankful to Vannevar Bush, one of the true titans of science in the 20th century.

Douglas Eby (Senior Fellow)
Boston Globe

From the article: Seventy-five years ago, President Franklin Delano Roosevelt penned a letter to his director of the Office of Scientific Research and Development, Dr. Vannevar Bush. Basking in the…

Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says: In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic.

Donald G. McNeil Jr. and Apoorva Mandavilli
New York Times

After years of prodding by patient advocates, federal officials on Wednesday sued the drug maker Gilead Sciences, charging that it had infringed government patents on the idea of preventing H…

Book Launch: Transparency in Health and Health Care in the United States

September 16, 2019
Watch Videos

Description In June 2019, Cambridge University Press published Transparency in Health and Health Care in the United States. This volume, edited by Holly Fernandez Lynch, I. Glenn Cohen, Carmel Shachar, and…

Grants

W. Nicholson Price (Academic Fellow Alumnus)
Berkeley Technology Law Journal

From the abstract: Innovation is a primary source of economic growth and is accordingly the target of substantial academic and government attention. Grants are a key tool in the government…

Drug Pricing Policies in the United States and Globally: From Development to Delivery

October 24, 2018
Watch Videos

Couldn't join us? Check out the conversation on Twitter: @PetrieFlom #drugpricing and some of our speakers' slide presentations below! Description This one-day conference explored the current pharmaceutical pricing landscape…

New Funding Frontiers: Innovative Funding Models in Translational Research

October 1, 2018

The working group briefing book is available now for download. Description This one-day working group and conference explored the challenges in pursuing for-profit private funding for early stage translational research.…

The Petrie-Flom Center Launches the Innovative Funding Models in Translational Research Project

The Petrie-Flom Center

January 30, 2018 - The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is launching the Innovative Funding Models in Translational Research Project to explore the bioethical,…

Bernie Sanders Tells Big Pharma: Stop Making Americans Pay Twice

Josh Keefe, quoting Rachel E. Sachs (Academic Fellow Alumna)
International Business Times

[...] Other experts told IBT federal support of drug development goes well beyond just funding research. “It’s not so much the money we are actually spending through NIH.…

Private Investment vs. Public Funding in Therapeutic Development: A Health Policy and Bioethics Consortium

May 12, 2017

Panelists Bhaven Sampat, PhD, Professor of Health Policy and Management, Columbia University Mailman School of Public Health Terry McGuire, MS, MBA, Founding Partner, Polaris Partners Learn more about the Health…

Junior Research Scholar, Sports and Society Program, NYU School of Professional Studies

Deadline: May 12, 2017
Brendan Parent

JR. RESEARCH SCHOLAR: NYU School of Professional Studies, Sports and Society Program We are seeking a researcher for the NYU SPS Sports and Society Program. It is an independent think…

2017 Call for Proposals: Policies for Action: Policy and Law Research to Build a Culture of Health, Robert Wood Johnson Foundation

Deadline: March 10, 2017, 3:00 p.m. ET
>Read full call

Purpose Policies for Action: Policy and Law Research to Build a Culture of Health (P4A) was created to help build the evidence base for policies that can help…

President-Elect Trump’s Health Policy Agenda: Priorities, Strategies, and Predictions

December 19, 2016
Watch Videos

The Petrie-Flom Center hosted a live web panel to address what health care reform might look like under President-elect Trump's administration. Expert panelists discussed the future of the Affordable…

Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits

Matt Richtel and Andrew Pollack, quoting Rachel E. Sachs (Academic Fellow alumna)
New York Times

From the article: Rachel Sachs, an associate law professor at Washington University in St. Louis and expert in innovation policy, said the government had every right to seek price concessions.…

Paying Research Participants: Ethical and Regulatory Parameters

December 9, 2016
Watch Videos

Couldn't make it to the event? Check out some of the speakers' slide presentations below! Description This symposium brought together a variety of experts to discuss key ethical and…

Big Data Neglects Populations Most in Need of Medical and Public Health Research and Interventions

Sarah E. Malanga, Jonathan D. Loe, Christopher T. Robertson (Academic Fellow alumnus), and Kenneth S. Ramos
Arizona Legal Studies Discussion Paper

Originally presented as a paper at the 2016 Petrie-Flom Center Annual Conference: Big Data, Health Law, and Bioethics. Check out the event website to watch video of this and other presentations! …

The FDA is prohibited from going germline

I. Glenn Cohen (Faculty Director) and Eli Y. Adashi
Science

Petrie-Flom Faculty Director I. Glenn Cohen has co-authored a new article in Science magazine addressing recent legislation preventing the FDA from approving any research "in which a human embryo is…

Review of Human subjects research regulation: perspectives on the future: by I. Glenn Cohen (Faculty Director) & Holly F. Lynch (Executive Director) (eds.):

Lydia Stewart Ferreira (Visiting Scholar)
Theoretical Medicine and Bioethics

Petrie-Flom Visiting Scholar Lydia Stewart Ferreira, currently Adjunct Professor at the University of Toronto Faculty of Law and Osgoode Hall Law School, recently published a review of I. Glenn Cohen …

Legal and Ethical Issues in Healthcare Start-Ups: (followed by Petrie-Flom's 2014 Open House)

October 6, 2014
Watch Videos

New healthcare start-ups face a range of legal and ethical challenges as they develop new products and services and solicit financial support from investors. Building on the success of the…

Do Fixed Patent Terms Distort Innovation?: Evidence from Cancer Clinical Trials

Eric B. Budish, Benjamin N. Roin, and Heidi Williams
Public Health Law & Policy e-Journal 5, no. 64

Abstract: Patents award innovators a fixed period of market exclusivity, e.g., 20 years in the United States. Yet, since in many industries firms file patents at the time of discovery (…

Responsibility and Integrity in the Pharmaceutical Industry

November 21, 2013

Video of this event is now available online: The Petrie-Flom Center hosted a lecture by Neil Flanzraich on responsible pricing strategy, access to care, clinical trial design, outsourcing, and other…

Health Law Workshop: Aaron Kesselheim

November 18, 2013

Presentation Professor Kesselheim's paper, "Do March-In Rights Protect Public Interests in Medical Products Arising from Federally-Funded Research?", is not available online. Please email Kaitlin Burroughs at kburroughs@law.harvard…

Pharma manufacturing woes dog industry

Sarah Moulton, quoting W. Nicholson Price II
Chemistry World

[...] While many of these problems arise from quality control failures, according to Nicholson Price from Harvard Law School’s Petrie-Flom centre for health law policy, biotechnology and bioethics, this…